Verrica Pharmaceuticals (VRCA) Common Equity (2021 - 2025)
Historic Common Equity for Verrica Pharmaceuticals (VRCA) over the last 5 years, with Q3 2025 value amounting to -$17.0 million.
- Verrica Pharmaceuticals' Common Equity rose 4995.74% to -$17.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$17.0 million, marking a year-over-year increase of 4995.74%. This contributed to the annual value of -$9.9 million for FY2024, which is 14989.12% down from last year.
- Per Verrica Pharmaceuticals' latest filing, its Common Equity stood at -$17.0 million for Q3 2025, which was up 4995.74% from -$17.5 million recorded in Q2 2025.
- Verrica Pharmaceuticals' 5-year Common Equity high stood at $64.8 million for Q1 2023, and its period low was -$34.1 million during Q3 2024.
- In the last 5 years, Verrica Pharmaceuticals' Common Equity had a median value of $25.4 million in 2022 and averaged $20.4 million.
- Per our database at Business Quant, Verrica Pharmaceuticals' Common Equity skyrocketed by 23919.06% in 2023 and then tumbled by 133183.02% in 2025.
- Over the past 5 years, Verrica Pharmaceuticals' Common Equity (Quarter) stood at $32.6 million in 2021, then rose by 22.78% to $40.0 million in 2022, then crashed by 50.63% to $19.8 million in 2023, then tumbled by 149.89% to -$9.9 million in 2024, then crashed by 72.82% to -$17.0 million in 2025.
- Its Common Equity was -$17.0 million in Q3 2025, compared to -$17.5 million in Q2 2025 and -$18.6 million in Q1 2025.